AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34444773
Drug: Heavy cream
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy cream (HC)
Trial: 32030887
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily until disease progression
Trial: 35089218
Drug: Febuxostat 40
RxNorm normalized name: febuxostat 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 40 mg daily before contrast agent and hydration
Trial: 33685500
Drug: Salvianolate 200
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvianolate 200 mg intravenously dripped for 30 min and then for 7 days
Trial: 33685500
Drug: Salvianolate 200
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvianolate 200 mg
Trial: 33120356
Drug: 10‐minute ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐minute ice massage prior to iontophoresis treatment
Trial: 34304234
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 30 mg/kg with IV placebo
Trial: 34304234
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 15 mg/kg with oral placebo
Trial: 32690730
Drug: Not using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not using drugs
Trial: 33837482
Drug: Pai‐Neng‐Da Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pai‐Neng‐Da Capsule (PNDC) 320 mg/d plus cyclosporine 5 mg/(kg·d) plus andriol 80 mg/d
Trial: 34438327
Drug: Riboflavin deficiency
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin deficiency diet (1.48 mg riboflavin/kg)
Trial: 34438327
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (16.48 mg riboflavin/kg)
Trial: 32958820
Drug: Elective nodal
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Trial: 32958820
Drug: Elective nodal
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Trial: 32958820
Drug: Conventional field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Trial: 32958820
Drug: Conventional field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Trial: 33338463
Drug: Standard ultrasound-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ultrasound-guided subacromial injections (40 mg triamcinolone acetonide)
Trial: 33338463
Drug: Dual-target injections
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target injections (20 mg triamcinolone acetonide for LHBT and supraspinatus tendons)
Trial: 33589279
Drug: Extended oral
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended oral antibiotic prophylaxis for 7 days after discharge
Trial: 33589279
Drug: No extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No extended oral antibiotic prophylaxis
Trial: 35416182
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g fish oil daily for 6 weeks
Trial: 35416182
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g soybean oil daily for 6 weeks
Trial: 35011059
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of each (fish oil and soybean oil) daily for 6 weeks
Trial: 33720388
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg sugammadex
Trial: 33894423
Drug: Placebo intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal spray
Trial: 36413792
Drug: Low-dose Ara-C
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Ara-C plus pegylated recombinant arginase BCT-100
Trial: 33582621
Drug: Action observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action observation therapy in addition to exercise (n = 18)
Trial: 32398113
Drug: Propranolol (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-80 mg twice daily) in addition to standard care
Trial: 32398113
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care alone (i.e. anti-epileptic drugs or headache treatments)
Trial: 36075235
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered after childbirth
Trial: 36075235
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered after childbirth
Trial: 33648495
Drug: Delay in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay in seeking treatment for pelvic organ prolapse
Trial: 33648495
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with delay in treatment
Trial: 32811613
Drug: Transcranial pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial pulsed ultrasound combined with alteplase intravenous thrombolysis
Trial: 32811613
Drug: Alteplase intravenous
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase intravenous thrombolytic treatment
Trial: 33032585
Drug: Curcumin 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 5% ointment
Trial: 33032585
Drug: Vaseline ointment
RxNorm normalized name: petrolatum Topical Ointment [Vaseline]
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaseline ointment (placebo)
Trial: 35096422
Drug: Suprachoroidal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA)
Trial: 35096422
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA)
Trial: 34438110
Drug: Lidocaine +
RxNorm normalized name: Lidocaine + Menthol Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine + Dexamethasone (3 cc 2% lidocaine + 1 cc dexamethasone, 4 mg)
Trial: 34438110
Drug: Lidocaine alone
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine alone (3 cc 2% lidocaine + 1 cc normal saline)
Trial: 32500131
Drug: Oral caffeine
RxNorm normalized name: caffeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral caffeine (5 mg/kg)
Trial: 32009778
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination (FDC) of gemigliptin (50 mg) and rosuvastatin (20 mg)
Trial: 32009778
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of gemigliptin (50 mg) and rosuvastatin (20 mg)
Trial: 34948486
Drug: Early occupational
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early occupational therapy intervention program
Trial: 33498049
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (150,000 IU daily for 3 days before surgery)
Trial: 32800386
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 μg) and vitamin-B12 (500 μg) supplementation
Trial: 36121303
Drug: DPE technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPE technique with ropivacaine 0.1% and sufentanil 0.5 μg/mL
Trial: 35159318
Drug: Selenium yeast
RxNorm normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day), n = 118
Trial: 32570237
Drug: Low-dose OIT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OIT (20 mL; n = 19)
Trial: 32570237
Drug: High-dose OIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose OIT (100 mL; n = 14)
Trial: 33103925
Drug: 20-session schema
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-session schema group therapy plus treatment as usual (TAU) (n = 28)
Trial: 33103925
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) alone (n = 14)
Trial: 36046952
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral melatonin liquid
Trial: 36046952
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral melatonin liquid
Trial: 33657114
Drug: Early convalescent
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early convalescent plasma (CP) therapy
Trial: 33657114
Drug: Deferred convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred convalescent plasma (CP) therapy
Trial: 33811684
Drug: Music Video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Video (MV) therapy
Trial: 34951444
Drug: CHD-PAL intervention
RxNorm normalized name: PEG-PAL
DrugBank: Pegvaliase (DB12839)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CHD-PAL intervention (eight 30-min videoconferencing sessions over 20 weeks with an interventionist + Fitbit + exercise prescription)
Trial: 34951444
Drug: Comparator (Fitbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (Fitbit + exercise prescription)
Trial: 35351445
Drug: Norgestrel 0.075
RxNorm normalized name: norgestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 0.075 mg progestogen-only pill
Trial: 33758132
Drug: 0.3 mg/mL
RxNorm normalized name: menthol 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/mL nalbuphine with 10 mL 0.1% ropivacaine
Trial: 33758132
Drug: 0.3 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/mL sufentanil with 10 mL 0.1% ropivacaine
Trial: 32552387
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/tablet) + anti-TB therapy
Trial: 32552387
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + anti-TB therapy
Trial: 32940699
Drug: COBRA-light treatment
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-light treatment arm
Trial: 32940699
Drug: COBRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA treatment arm
Trial: 32974656
Drug: Internet-delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) for adolescents
Trial: 32974656
Drug: Internet-delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) for parents
Trial: 32807267
Drug: Healive vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healive vaccine
Trial: 32807267
Drug: Havrix vaccine
RxNorm normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix vaccine
Trial: 33796993
Drug: Furosemide (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.05 to 0.4 mg/kg/h)
Trial: 33301221
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) 13.8 g (two doses)
Trial: 33301221
Drug: Bisacodyl 10
RxNorm normalized name: bisacodyl 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisacodyl 10 mg
Trial: 33765513
Drug: lapatinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lapatinib + trastuzumab (L+T)
Trial: 33765513
Drug: trastuzumab followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab followed by lapatinib (T→L)
Trial: 35285241
Drug: Sutezolid 300
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 300 mg
Trial: 35285241
Drug: Sutezolid 600
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 600 mg
Trial: 35285241
Drug: Sutezolid 1200
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 1200 mg
Trial: 35285241
Drug: Sutezolid 1800
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 1800 mg
Trial: 35285241
Drug: Sutezolid (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid (all doses)
Trial: 34006328
Drug: Daily tablet
RxNorm normalized name: One-Daily Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tablet PrEP
Trial: 34006328
Drug: PrEP injection
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP injection or implant
Trial: 34006328
Drug: On-base locations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-base locations for lab evaluation and medication pick-up
Trial: 32129892
Drug: Immunosuppressant (IS)
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunosuppressant (IS) dose reduction
Trial: 35177108
Drug: OPIOID (hydrocodone/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPIOID (hydrocodone/acetaminophen 5/300 mg)
Trial: 35177108
Drug: NON‐OPIOID (ibuprofen/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NON‐OPIOID (ibuprofen/acetaminophen 400/500 mg)
Trial: 32223762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving traditional oral health information
Trial: 33508778
Drug: Regular ball
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular ball warm-up (156 g)
Trial: 33508778
Drug: Heavier ball
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavier ball warm-up (171.6 g)
Trial: 33508778
Drug: Lighter ball
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lighter ball warm-up (140.4 g)
Trial: 35440501
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg/day
Trial: 35576290
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration steroid therapy
Trial: 35576290
Drug: Long duration
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long duration steroid therapy
Trial: 33347019
Drug: Nanocurcumin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (160 mg/d)
Trial: 32791940
Drug: Prior antiplatelet
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior antiplatelet therapy
Trial: 32791940
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior antiplatelet therapy
Trial: 32692952
Drug: ACLC patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLC patch
Trial: 32692952
Drug: ACLC patch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACLC patch, oblique brace, anterior brace
Trial: 36257847
Drug: Colostomy closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostomy closure without mechanical bowel preparation (MBP)
Trial: 36257847
Drug: Colostomy closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostomy closure with mechanical bowel preparation (MBP)
Trial: 35681510
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin
Trial: 35033226
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone
Trial: 35033226
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with low-dose radiotherapy (0.5 Gy delivered twice per day for 2 days during each of the first four cycles)
Trial: 35033226
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only)
Trial: 33272839
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy (four-week sessions over one month)
Trial: 34865686
Drug: Binary dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Binary dance rhythm (12 weeks, twice a week, 45 minutes)
Trial: 34865686
Drug: Quaternary dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quaternary dance rhythm (12 weeks, twice a week, 45 minutes)
Trial: 34800427
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg once per day until discharge)
Trial: 36999805
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia
Trial: 34460181
Drug: Adding SGLT2
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding SGLT2 inhibitors
Trial: 34460181
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to GLP-1 receptor agonists (GLP-1 RAs)
Trial: 32057125
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate treatment
Trial: 36204125
Drug: Low-dose NW
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NW Low-Glu® (4 capsules per day)
Trial: 36204125
Drug: High-dose NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NW Low-Glu® (5 capsules per day)
Trial: 36204125
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg per day)
Trial: 33337815
Drug: EtaBS (Enerceptan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtaBS (Enerceptan) 50 mg weekly for 32 weeks
Trial: 33337815
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg weekly for 32 weeks
Trial: 33136471
Drug: Irinotecan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (60 mg/m2, days 1, 8, 15) plus cisplatin (60 mg/m2, day 1)
Trial: 33136471
Drug: Etoposide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (100 mg/m2, days 1‐3) plus cisplatin (80 mg/m2, day 1)
Trial: 35368946
Drug: Basic chemotherapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic chemotherapy combined with docetaxel
Trial: 34791970
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (210 mg of anthocyanins) for 7 days
Trial: 34791970
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (210 mg of anthocyanins) for 14 days
Trial: 34791970
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (210 mg of anthocyanins) for 7 days during walking
Trial: 34791970
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (210 mg of anthocyanins) for 14 days during walking
Trial: 32112999
Drug: Topical lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine-prilocaine cream
Trial: 32112999
Drug: Rectal meloxicam
RxNorm normalized name: meloxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal meloxicam suppository 15 mg